Filis Andreas, Engellandt Kay, Romualdo Sergio M F, El-Battrawy Ibrahim, Podlesek Dino, Juratli Tareq A, Eyüpoglu Ilker Y, Hijazi Mido Max
Department of Neurosurgery, Technische Universität Dresden, Faculty of Medicine, and University Hospital Carl Gustav Carus, Fetscherstrasse 74, 01307 Dresden, Germany.
Institute of Diagnostic and Interventional Neuroradiology, Technische Universität Dresden, Faculty of Medicine, and University Hospital Carl Gustav Carus, Fetscherstrasse 74, 01307 Dresden, Germany.
Diagnostics (Basel). 2024 Mar 8;14(6):581. doi: 10.3390/diagnostics14060581.
Successful treatment of spinal dural arteriovenous fistulas (SDAVF) requires prompt diagnosis with definitive fistula localization and non-delayed treatment. Magnetic resonance imaging (MRI) is used for the screening and follow-up of SDAVF, although the value of MRI signs such as myelopathy and flow voids is controversial. Therefore, we investigated the predictive value of MRI signs pre- and post-treatment and their correlation with the neurological status of SDAVF patients.
We retrospectively analyzed the clinical records of 81 patients who underwent surgical or endovascular treatment for SDAVF at our hospital between 2002 and 2023. A total of 41 SDAVF patients with follow-up MRI of 4.6 [2.9-6.5] months (median [interquartile range]) post-treatment and clinical follow-up of 3, 6, and 12 months were included.
The extent of pretreatment myelopathy was seven [6-8] vertebral levels, with follow-up MRI showing no myelopathy in 70.7% of cases. The pretreatment flow voids extended over seven [4.5-10] vertebral levels and completely disappeared on follow-up MRI in 100% of cases. The modified Aminoff-Logue scale of disability (mALS) was four [2-7] pretreatment and two [0-4.5] at the third follow-up, with improvement in 65.9% of patients. The American Spinal Injury Association motor score (ASIA-MS) was 97 [88-100] pretreatment and 100 [95-100] at the third follow-up assessment, with 78% of patients improving. Pretreatment ASIA-MS correlated with the extent of myelopathy at admission (R: 0.179; 95% CI: -0.185, -0.033; = 0.006) but not with flow voids at admission, while pretreatment mALS showed no correlation with either MRI signs. The improvement in ASIA-MS and mALS between admission and the last follow-up showed no correlation with the extent of pretreatment myelopathy and flow voids or with pos-treatment MRI changes. The diagnostic sensitivity of magnetic resonance angiography (MRA) for localization of the fistula was 68.3% (28/41).
The severity of the clinical condition in SDAVF patients has a multifactorial cause, whereby the ASIA-MS correlates with the extent of myelopathy pretreatment. MRI changes after treatment showed no correlation with the clinical outcome and cannot be used as a prognostic factor.
成功治疗脊髓硬脊膜动静脉瘘(SDAVF)需要及时诊断并明确瘘管定位,且治疗不能延迟。磁共振成像(MRI)用于SDAVF的筛查和随访,尽管诸如脊髓病和流空信号等MRI征象的价值存在争议。因此,我们研究了治疗前后MRI征象的预测价值及其与SDAVF患者神经状态的相关性。
我们回顾性分析了2002年至2023年在我院接受手术或血管内治疗的81例SDAVF患者的临床记录。纳入了41例SDAVF患者,其治疗后4.6 [2.9 - 6.5]个月(中位数[四分位间距])进行了随访MRI检查,并在3、6和12个月进行了临床随访。
治疗前脊髓病的范围为7 [6 - 8]个椎体节段,随访MRI显示70.7%的病例无脊髓病。治疗前的流空信号延伸至7 [4.5 - 10]个椎体节段,随访MRI显示100%的病例完全消失。改良的阿明诺夫 - 洛格残疾量表(mALS)治疗前为4 [2 - 7],第三次随访时为2 [0 - 4.5],65.9%的患者有所改善。美国脊髓损伤协会运动评分(ASIA - MS)治疗前为97 [88 - 100],第三次随访评估时为100 [95 - 100],78%的患者有所改善。治疗前的ASIA - MS与入院时脊髓病的范围相关(R:0.179;95% CI: - 0.185, - 0.033;P = 0.006),但与入院时的流空信号无关,而治疗前的mALS与任何MRI征象均无相关性。入院与最后一次随访之间ASIA - MS和mALS的改善与治疗前脊髓病和流空信号的范围或治疗后MRI变化均无相关性。磁共振血管造影(MRA)对瘘管定位的诊断敏感性为68.3%(28/41)。
SDAVF患者临床状况的严重程度有多种因素,其中ASIA - MS与治疗前脊髓病的范围相关。治疗后的MRI变化与临床结果无关,不能用作预后因素。